Skip Navigation



JAC Advance Access published online on July 23, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn303
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/5/1101    most recent
dkn303v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Klein, P.
Right arrow Articles by Scalise, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klein, P.
Right arrow Articles by Scalise, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum

Pavel Klein1,*, Oscar Cirioni2, Andrea Giacometti2 and Giorgio Scalise2

1 Institute of Animal Science, Praha 10, Uhrineves, Czech Republic 2 Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy

Received 12 March 2008; returned 26 May 2008; revised 10 June 2008; accepted 2 July 2008

* Corresponding author. Tel: +420-775-224-887; Fax: +420-267-710-779; E-mail: pavel.klein{at}seznam.cz

Objectives: The aim of this study was to assess the effect of commercial aurintricarboxylic acid (ATA) against Cryptosporidium parvum.

Methods: The anticryptosporidial effect of ATA was evaluated in vitro using cell culture and double fluorogenic staining, and in vivo in experimentally infected neonatal C57BL/6 mice. Mice were orally treated for 9 consecutive days starting on the day of infection with daily ATA doses of 50 and 100 µmol/kg. Paromomycin (100 mg/kg) was used as a positive control.

Results: In both in vitro models, ATA at concentrations of 100 and 10 µmol/L completely inhibited sporozoites within 10 and 60 min, respectively. Viability of oocysts exposed to 100 µmol/L and assessed by flow cytometry and in cell culture was reduced by 65% and 61%, respectively. The treatment of neonatal mice with a daily ATA dose of 100 µmol/kg led to 97–99% inhibition of infection without any observable negative effects on the animals. In comparison, the mean reduction of infection for paromomycin was 79–84%.

Conclusions: ATA exerted high anticryptosporidial activity and should be considered for further study.

Key Words: flow cytometry , cell culture , chemotherapy , experimental infection , neonatal mice


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.